In this study, we used a stepwise CRISPR/Cas9 screens in combination of proteomic analyses to identify a CUL5-E3 ligase complex as an important negative regulator of TCR/IL2 signaling and anti-tumor effector activity in CD8+ T cells. This evidence concerns the gene CUL5 and neoplasm.